Aortic Stenosis News and Research

RSS

TAVI-first strategy proves noninferior to PCI-first approach in new trial

A TAVI-first strategy was noninferior to a PCI-first strategy after one years' follow-up, according to results presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine.

30 Aug 2026

Gum disease bacteria linked to calcific aortic valve stenosis

Gum disease bacteria may spur calcium buildup in the heart's aortic valve, leading to a common and serious heart valve disease, according to preliminary, independent research presented at the American Heart Association's Basic Cardiovascular Sciences Scientific Sessions 2026.

12 Jul 2026

Landmark study confirms long-term durability of Ross procedure for aortic valve replacement

The Ross procedure, a highly specialized option for aortic valve replacement, is associated with significant long-term durability and excellent outcomes in a wide range of adult patients with aortic valve disease.

23 Jun 2026

Role of coronary revascularization in TAVI patients with severe aortic stenosis and CAD

The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during EuroPCR 2026 and are set to impact practice worldwide.

20 May 2026

Email alerts boost valve replacement rates in older patients with aortic stenosis

New data finds older patients with severe aortic stenosis (AS) were more likely to receive aortic valve replacement (AVR) and survive when clinicians received automated email notifications with abnormal heart ultrasound results detecting AS.

25 Apr 2026

Novel algorithm improves detection of moderate-to-severe aortic stenosis

A novel detection algorithm spotted moderate-to-severe aortic stenosis (AS) with a sensitivity of 90.5% of all patients and 100% of African American patients.

24 Apr 2026

Tirzepatide significantly reduces cardiovascular risk in high-risk patients

Two new studies show that tirzepatide, a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist (RA), significantly reduces cardiovascular risk in high-risk patients, including those undergoing percutaneous coronary intervention (PCI) and those with obesity undergoing transcatheter aortic valve replacement (TAVR).

23 Apr 2026

Study supports safe same-day discharge following TAVI procedures

With careful selection, same-day hospital discharge was found to be feasible and safe in around one-fifth of patients undergoing transcatheter aortic valve implantation in a study presented today at the EAPCI Summit 2026.

19 Feb 2026

AI-powered stethoscopes enable early detection of heart valve disease

Artificial intelligence could help doctors detect serious heart valve disease years earlier, potentially saving thousands of lives, a new study suggests.

10 Feb 2026

Interventions to treat valvular heart disease in cancer patients significantly improve survival

Valvular heart disease, identified through cardiovascular imaging, is common in cancer patients. Interventions to treat valvular heart disease significantly improved survival.

11 Dec 2025

New initiative aims to accelerate aortic stenosis diagnosis and treatment

People living with aortic stenosis (AS) could gain earlier access to innovative care and treatment thanks to a new effort from the American Heart Association designed to boost clinical trial participation and speed diagnosis of this common but underdiagnosed heart valve condition.

4 Nov 2025

Clinically significant valvular heart disease vastly underdiagnosed in U.S. elders

Results from the PREVUE-VALVE study suggest that there are currently at least 4.7 million people aged 65-85 living with moderate or greater valvular heart disease (VHD) in the United States, and at least 10.6 million with clinically significant VHD, most of whom are unaware of their condition.

28 Oct 2025

Multimodal AI brings a new dimension to cardiovascular medicine

Although artificial intelligence has already shown promise in cardiovascular medicine, most existing tools analyze only one type of data—such as electrocardiograms or cardiac images—limiting their clinical utility.

10 Oct 2025

Updated guidelines aim to standardize valvular heart disease care across Europe

Updated ESC/EACTS Guidelines, being published today at ESC Congress 2025, aim to improve the way that patients with valvular heart disease are diagnosed and treated, responding to robust new evidence that suggests some newer and less invasive treatments could be offered more widely and consistently to patients.

30 Aug 2025

REBOOT trial finds no benefit of beta blockers after uncomplicated heart attacks

Beta blockers-drugs commonly prescribed for a range of cardiac conditions, including heart attacks-provide no clinical benefit for patients who have had an uncomplicated myocardial infarction with preserved heart function.

30 Aug 2025

New initiative expands screening for cardiovascular disease marker in community health centers

Elevated lipoprotein(a), also known as Lp(a), is an independent, inherited and causal risk factor for cardiovascular disease, the leading cause of death and disability worldwide.

5 Aug 2025

New project aims to boost screening for cardiovascular disease marker in community health centers

Elevated lipoprotein(a), also known as Lp(a), is an independent, inherited and causal risk factor for cardiovascular disease, the leading cause of death and disability worldwide.

23 Jul 2025

Dual treatment strategy offers survival advantage for patients with severe heart disease

Aortic valve narrowing (aortic stenosis) with concomitant cardiac amyloidosis is a severe heart disease of old age that is associated with a high risk of death.

2 Jun 2025

Scientists develop advanced MRI technology to diagnose aortic stenosis

University of East Anglia scientists have developed cutting-edge MRI technology to diagnose a common heart problem more quickly and accurately than ever before.

8 May 2025

Early TAVR shows greatest stroke reduction in patients aged 65 to 70

New analysis from the EARLY TAVR trial showed patients between the age of 65 and 70 years old derived the most benefits of a strategy of early intervention with transcatheter aortic valve replacement (TAVR) compared to other age groups, especially in regards to stroke risk, and in regards to the composite of death, stroke, and heart failure hospitalization.

2 May 2025